Please login to the form below
Non-muscle-invasive bladder cancer
This page shows the latest Non-muscle-invasive bladder cancer news and features for those working in and with pharma, biotech and healthcare.
AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail
Despite the withdrawal, AZ still has several phase 3 trials testing Imfinzi in various treatment combinations for early- and late-stage bladder cancer. ... This includes the phase 3 NILE trial in metastatic disease, the phase 3 NIAGARA trial in muscle
Latest news
-
AstraZeneca’s Imfinzi fails first-line bladder cancer test
AZ’s head of oncology José Baselga said that Imfinzi is still in a “comprehensive” phase 3 programme in bladder cancer. ... pre-surgery) bladder cancer treatment, and the POTOMAC study, which include subjects with non-muscle invasive bladder
-
Tocagen merges with Forte Biosciences after brain cancer fail
of brain cancer. ... and non-muscle invasive bladder cancer.
-
Keytruda claims first place in bladder cancer race
for non-muscle-invasive bladder cancer (NMIBC), extending its lead in the checkpoint inhibitor market. ... NMIBC is the most commonly encountered form of bladder cancer, accounting for around 75% of the 80, 000 new cases of bladder cancer seen every year
-
FDA panel clears Keytruda for hard-to-treat bladder cancer
The Oncologic Drugs Advisory Committee (ODAC) voted nine to four that Keytruda (pembrolizumab) should be approved for the treatment of certain patients with high-risk, non-muscle-invasive bladder cancer (NMIBC), ... Merck estimates more than 80, 000 new
-
A look ahead to key trial readouts at ESMO
Merck &Co/MSD – already dominating non-small cell lung cancer with Keytruda (pembrolizumab) – will have overall survival data for its drug in first-line squamous head and neck cancer from the ... It will also have mid-stage data on the drug as a
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2015
Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.
-
Achieving consensus
Their joint aim: to facilitate uniform use of fluorescence cystoscopy in the diagnosis and follow up of bladder cancer, with the ultimate goal of improved care and better outcomes for patients. ... Despite widespread acceptance of the evidence for
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Account Management
-
Competitive Salary Offered
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Associate Account Director
-
Competitive Salary
-
Senior Medical Writer
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Medical Editor
-
Competitive Salary
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Senior Account Executive
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Account Manager
-
Competitive Salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Merck & Co reveals plans for women’s health spinoff Organon
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- bluebird bio aiming to separate business units by year-end
- InSite Events™ selected as an honorable mention in Fast Company’s 2021 World Changing Ideas Awards
- THE HIDDEN LIFESAVERS: overdose prevention campaign launches nationwide
- Moderna’s booster vaccines increase neutralising antibodies against COVID-19 variants
- FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer
- US backs proposal to waive IP protection for COVID-19 vaccines
- Nanobiotechnology, Artificial Intelligence, and Virtual Care
- Why female mentorship is so powerful in pharma
- CanSinoBIO considers booster jab for COVID-19 vaccine
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Moderna COVID-19 vaccine shortfall could affect UK supply
- NICE sets out plans for ‘ambitious’ five-year strategy
- Working in true partnership in a time of change
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
- Deep 6 AI: the smart software breathing new life into clinical trials
- Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
- COVID-proof: How Teams are Creating Launch Intensity thru Adversity
- Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
